BCM-599 is a HBV capsid assembly inhibitor. BCM-599 could be utilized as an effective combination treatment against HBV infection. BCM-599 showed IC50 of 0.88 μM and CC50 of 144 μM in HepG2.2.15 cells. BCM-599 decreased both intracellular and extracellular viral DNA levels without affecting the pgRNA level; moreover, interestingly, at the concentration of 0.88 μM, BCM-599 reduced the intracellular capsid level by 51% while increased the amount of free core protein dimer by 5-fold. References: Cho MH, Jeong H, Kim YS, Kim JW, Jung G. 2-amino-N-(2,6-dichloropyridin-3-yl)acetamide derivatives as a novel class of HBV capsid assembly inhibitor. J Viral Hepat. 2014 Dec;21(12):843-52. doi: 10.1111/jvh.12214. Epub 2013 Dec 25. PubMed PMID: 24372792.

纯度：≥98%

CAS：1820763-99-2